# Jedd D. Wolchok

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jedd-d-wolchok/

## Facts

| Field | Value |
| --- | --- |
| Citations | 209,541 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 176 |
| i10-index | 554 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5054656505 |
| ORCID iD | https://orcid.org/0000-0001-6718-2222 |
| Works | 1,448 |

## Researcher papers

Showing 12 of 16.

- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)
- [Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade](https://scholariq.org/papers/clonal-neoantigens-elicit-t-cell-immunoreactivity-and-sensitivity-to-immune/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing](https://scholariq.org/papers/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti/)
- [Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy](https://scholariq.org/papers/pneumonitis-in-patients-treated-with-anti-programmed-death-1-programmed-death/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors](https://scholariq.org/papers/clinicopathological-features-of-acute-kidney-injury-associated-with-immune/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.